Citigroup
CLVS

Citigroup’s Clovis Oncology, Inc. CLVS Stock Holding History

Citigroup’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,752
Closed -$2K – 6134
2022
Q3 		$2K Sell
1,752
-35,963
-95% -$56.1K ﹤0.01% 5587
2022
Q2 		$68K Sell
37,715
-101,204
-73% -$149K ﹤0.01% 4405
2022
Q1 		$281K Sell
138,919
-881,432
-86% -$1.73M ﹤0.01% 3880
2021
Q4 		$2.77M Buy
1,020,351
+557,021
+120% +$2.06M ﹤0.01% 2349
2021
Q3 		$2.07M Sell
463,330
-226,429
-33% -$1.09M ﹤0.01% 2520
2021
Q2 		$4M Buy
689,759
+501
+0.1% +$2.94K ﹤0.01% 2104
2021
Q1 		$4.84M Buy
689,258
+665,154
+2,760% +$4.46M ﹤0.01% 1808
2020
Q4 		$116K Sell
24,104
-3,642
-13% -$18.4K ﹤0.01% 5425
2020
Q3 		$162K Sell
27,746
-157,790
-85% -$944K ﹤0.01% 4769
2020
Q2 		$1.25M Buy
185,536
+42,179
+29% +$319K ﹤0.01% 3315
2020
Q1 		$912K Buy
143,357
+37,061
+35% +$297K ﹤0.01% 3279
2019
Q4 		$1.11M Buy
106,296
+45,416
+75% +$330K ﹤0.01% 3645
2019
Q3 		$239K Sell
60,880
-313,822
-84% -$2.54M ﹤0.01% 5009
2019
Q2 		$5.57M Buy
374,702
+354,347
+1,741% +$6.4M ﹤0.01% 1879
2019
Q1 		$505K Sell
20,355
-345,546
-94% -$8.66M ﹤0.01% 4172
2018
Q4 		$6.57M Buy
365,901
+279,510
+324% +$5.71M 0.01% 1594
2018
Q3 		$2.54M Buy
86,391
+71,763
+491% +$2.78M ﹤0.01% 2517
2018
Q2 		$665K Sell
14,628
-125,096
-90% -$6.08M ﹤0.01% 3791
2018
Q1 		$7.38M Buy
139,724
+80,581
+136% +$4.7M 0.01% 1458
2017
Q4 		$4.02M Sell
59,143
-226,430
-79% -$15.8M ﹤0.01% 2046
2017
Q3 		$23.5M Sell
285,573
-1,970
-0.7% -$156K 0.02% 714
2017
Q2 		$26.9M Sell
287,543
-139,156
-33% -$8.51M 0.02% 622
2017
Q1 		$27.2M Buy
426,699
+179,057
+72% +$10.9M 0.02% 616
2016
Q4 		$11M Buy
247,642
+210,927
+574% +$7.42M 0.01% 1123
2016
Q3 		$1.32M Buy
36,715
+35,773
+3,798% +$768K ﹤0.01% 2916
2016
Q2 		$13K Sell
942
-35,535
-97% -$519K ﹤0.01% 6427
2016
Q1 		$700K Buy
36,477
+28,922
+383% +$612K ﹤0.01% 3758
2015
Q4 		$264K Sell
7,555
-52,257
-87% -$3.37M ﹤0.01% 4486
2015
Q3 		$5.5M Buy
59,812
+37,971
+174% +$3.29M 0.01% 1583
2015
Q2 		$1.92M Sell
21,841
-12,034
-36% -$1.03M ﹤0.01% 2558
2015
Q1 		$2.52M Buy
33,875
+18,544
+121% +$1.31M ﹤0.01% 2283
2014
Q4 		$859K Buy
15,331
+1,065
+7% +$56K ﹤0.01% 3303
2014
Q3 		$648K Buy
14,266
+6,467
+83% +$270K ﹤0.01% 3343
2014
Q2 		$323K Sell
7,799
-489
-6% -$25.2K ﹤0.01% 3751
2014
Q1 		$573K Sell
8,288
-2,614
-24% -$192K ﹤0.01% 3342
2013
Q4 		$658K Buy
10,902
+187
+2% +$10.2K ﹤0.01% 3561
2013
Q3 		$652K Buy
10,715
+10,397
+3,269% +$737K ﹤0.01% 3235
2013
Q2 		$21K Buy
+318
New +$14.3K ﹤0.01% 5816

Other funds holding CLVS

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CAS
Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return
CASC
Coppell Advisory Solutions Corp Coppell, Texas $531M AUM
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
FFWM
Future Financial Wealth Management Cincinnati, Ohio $155M AUM 13% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Citigroup's CLVS Position: Q4 2022 in Review

Citigroup sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 1,752 shares — an estimated $2K sold.

Citigroup first reported a position in CLVS in Q2 2013 and held it in 38 quarters. The position peaked at $27.2M in Q1 2017. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

  • Citigroup reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
  • Citigroup sold 1,752 Clovis Oncology, Inc. shares in Q4 2022, an estimated $2K.
  • Citigroup first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 38 quarters.
  • Citigroup's Clovis Oncology, Inc. position peaked at $27.2M in Q1 2017.
  • 15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Citigroup's 13F filing for Q4 2022, filed 9 Feb 2023.